Cell Transplantation in Multiple Sclerosis: Experiences, Questions and Problems

Abstract

Scientific background: Autologous haematopoietic stem cell transplantation is an immunosuppressive treatment used to sustain long­term stabilization of multiple sclerosis (MS). The clinical efficacy of this therapy needs to be proved by studies comparing its effect with other treatments formerly shown to be effective in MS, such as mitoxantrone. High dose immunosuppressive treatment together with haematopoietic stem cell transplantation has high mortality risk. For this reason, before suggesting these treatments to the patients we should think carefully. Conclusion: Although, MS cases with low EDSS scores and gadolinium­enhancement in brain MRI, and young patients with proggressive disease course are suggested as the most suitable candidates for haematopoietic stem cell transplantation in medical literature, it must be remembered that there is no study comparing its clinical efficacy and efficiency with the formerly approved drugs to treat MS.